

57th Annual Meeting of the Japanese Society of Neurology

[Day 2] May 19 (Thu.)

Symposium Educational Session Oral Session Social Event

E English Session

		7:00	8:00	9:00	10:00	11:00	12:00	13:00	14:00	15:00	16:00	17:00	18:00	19:00	20:00	21:00	
Kobe International Exhibition Hall	Hall No.2 Building 1F	Room 1 Convention Hall				Oral Session O-12 CVD (Clinical research)		President Lecture	Members Meeting	Prize Awards	Special Lecture	Seminar Lecture 01					
	Hall No.1 Building 2F	Room 2 Exhibition Hall A	Toward Treatable Neurology 04 Acute treatment and secondary prevention of stroke: The breaking evidences			Oral Session O-13 CVD (Medical treatment)	LS-12 DAIICHI SANKYO. CO.,LTD				Hot Topics 07 Embollic strokes of undetermined source (ESUS): a new therapeutic target					J-1 Resident Clinical Tournament	
		Room 3 Exhibition Hall B	Symposium 06 Interdisciplinary approach for pathophysiological clarification against three major neurodegenerative dementia disorders			Oral Session O-14 Dementia (Clinical research 1 (Japanese))	LS-13 GlaxoSmithKline K.K.				Symposium 09 A large dementia cohort study in Japan: the identification of targets						
	Hall No.2 Building 3F	Room 4 Room 3A	Lecture Marathon LM-04 LM-05 LM-06			Oral Session O-15 MND (Clinical and basic research)	LS-14 Mitsubishi Tanabe Pharma Corporation				Lecture Marathon LM-07 LM-08				ES-01 Novartis Pharma K.K.		
	Hall No.2 Building 2F	Room 5 Room 2A		Neuro CPC			Oral Session O-16 Neuropathology	LS-15 Nippon Zoki Pharmaceutical Co., Ltd.									
	Hall No.2 Building 3F	Room 6 Room 3B	MEX-01 Biogen Japan Ltd.				Oral Session O-17 Epilepsy	LS-16 Astellas Pharma Inc.				Hot Topics 08 Molecular dissection of spastic paraplegia					
Kobe Portopia Hotel	Main Building B1 F	Room 7 Kairaku 1		Symposium 07 Disruption of glia-neuron assemblies in intractable neurological disorders			Oral Session O-18 Central autoimmune diseases (Clinical and basic research 1)	LS-17 ONO PHARMACEUTICAL CO., LTD.									
		Room 8 Kairaku 2		New Guideline 02 Diagnostic and therapeutic management based on the clinical guideline of herpes simplex encephalitis 2015			Oral Session O-19 Neuroinfectious diseases/prion	LS-18 Sumitomo Dainippon Pharma Co., Ltd.			Symposium 10 The Interface of Neurology and Sleep Medicine				ES-02 FUJIFILM RI Pharma Co., Ltd./Under the auspice of: The Japanese Council of Nuclear Neuroimaging/Japanese Society of Nuclear Medicine		
		Room 9 Kairaku 3		Neuroscience Frontier Symposium 01 Next-generation neurogenetics: cutting-edge strategies for understanding neurological disorders			Oral Session O-20 Neurogenetics/ Gene therapy	LS-19 Biogen Japan Ltd.			New Guideline 03 Japanese Guidelines for the Diagnosis and Treatment of Dystonia: An Overview				Premium Evening Seminar Actelion Pharmaceuticals Japan Ltd.		Information Sharing for Premium Evening Seminar Venue: (Waraku) Main Building B1F Actelion Pharmaceuticals Japan Ltd.
Kobe International Conference Center	1-1-1-1	Room 10 Main Hall		Toward Treatable Neurology 05 Recent advance of clinical trials and treatment in progressive supranuclear palsy			Oral Session O-21 PD (Clinical research 2)	LS-20 FP Pharmaceutical Corporation			Toward Treatable Neurology 06 Improvement in the management of Parkinson's disease: Present status and prospect of ultra-early diagnosis						
	3-1-1-1	Room 11 International Conference Hall		Asia Initiative Session 01 Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) in Asia			Oral Session O-22 CVD (Pathophysiology)	LS-21 Novartis Pharma K.K.			Asia Initiative Session 02 X-linked Dystonia Parkinsonism				ES-03 Bayer Yakuhin, Ltd.		
	3-1-1-2	Room 12 Reception Hall															
	4-1-1-1	Room 13 Meeting Room 401+402		Symposium 08 Work sharing for neurologists			Oral Session O-24 PD/PSP (Treatment)	LS-22 Pfizer Japan Inc.									
	5-1-1-1	Room 14 Meeting Room 501		Hot Topics 06 Neuroregeneration and nucleic acid medicine			Oral Session O-25 AD (Diagnosis/Treatment)	LS-23 Otsuka Pharmaceutical Co., Ltd.									
	5-1-1-2	Room 15 Meeting Room 502	MEX-02 FP Pharmaceutical Corporation				Oral Session O-26 Peripheral neuropathy/ Metabolic disorders	LS-24 Genzyme Japan K.K.			Hot Topics 09 Combining imaging and therapy: Neuroimaging-based companion diagnostics and therapeutics						
4-1-1-3	Room 16 Meeting Room 403		International Educational Session 02 How to diagnose and treat MMN; an ALS mimic			Oral Session O-23 Central autoimmune diseases (Clinical and basic research 2)				International Educational Session 03 How to Manage Seizures							
Exhibition Hall	1	Poster Session Hall No.3 Building		Poster Preparation				Poster Round		Poster Round			Poster Session			Poster Removal	